Therapy Areas: Oncology
Guardant Health expands liquid biopsy test with AI-powered epigenomic applications
11 November 2026 - Precision oncology company Guardant Health Inc (Nasdaq: GH) announced on Wednesday that it has expanded its Guardant360 Liquid cancer testing capabilities with new epigenomic applic...
Nuvation Bio to present at Jefferies Global Healthcare Conference in London
11 November 2026 - Nuvation Bio Inc (NYSE: NUVB), a New York-based global oncology company involved in cancer treatment, announced on Tuesday that David Hung, MD, founder, president, and chief executi...
Abbisko Therapeutics' PIMJETMI receives US FDA approval to treat tenosynovial giant cell tumour (TGCT)
11 November 2026 - Abbisko Therapeutics Co Ltd (HKEX code: 02256.HK), a China-based biopharmaceutical company, announced on Tuesday that the US Food and Drug Administration (FDA) has approved PIMJETMI...
Illumina expands MRD research portfolio with ultrasensitive sequencing technology
9 November 2026 - Genome research company Illumina Inc (NASDAQ: ILMN) announced on Monday that it has expanded its molecular residual disease (MRD) research portfolio with an early access programme fo...
Photocure maintains 2028 Medicare coverage target for AssureMDx following CMS update
9 November 2026 - Diagnostic company Photocure ASA (OSE: PHO) confirmed on Monday that the anticipated Medicare coverage timeline for its AssureMDx bladder cancer test remains aligned with its origina...
RYBREVANT FASPRO co-formulated with Halozyme's ENHANZE technology approved by US FDA in advanced head and neck cancer
9 November 2026 - Biotechnology company Halozyme Therapeutics Inc (Nasdaq:HALO) announced on Friday that Johnson & Johnson (NYSE:JNJ) was granted accelerated approval from the US Food and Drug Adm...